REGEND 005
Alternative Names: REGEND-005Latest Information Update: 23 Jan 2023
At a glance
- Originator Regend Therapeutics
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Kidney disorders
Most Recent Events
- 20 Dec 2022 Regend Therapeutics plans IND-enabling studies in 2023 (Regend Therapeutics pipeline, December 2022).
- 16 Dec 2022 Preclinical trials in Kidney disorders in China (Parenteral), prior to December 2022 (Regend Therapeutics pipeline, December 2022)